Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Top Cited Papers
- 29 January 2015
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 372 (5), 436-446
- https://doi.org/10.1056/nejmoa1412379
Abstract
Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor–positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain. We randomly assigned 3066 premenopausal women, stratified according to prior receipt or nonreceipt of chemotherapy, to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression. The primary analysis tested the hypothesis that tamoxifen plus ovarian suppression would improve disease-free survival, as compared with tamoxifen alone. In the primary analysis, 46.7% of the patients had not received chemotherapy previously, and 53.3% had received chemotherapy and remained premenopausal. After a median follow-up of 67 months, the estimated disease-free survival rate at 5 years was 86.6% in the tamoxifen–ovarian suppression group and 84.7% in the tamoxifen group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.83; 95% confidence interval [CI], 0.66 to 1.04; P=0.10). Multivariable allowance for prognostic factors suggested a greater treatment effect with tamoxifen plus ovarian suppression than with tamoxifen alone (hazard ratio, 0.78; 95% CI, 0.62 to 0.98). Most recurrences occurred in patients who had received prior chemotherapy, among whom the rate of freedom from breast cancer at 5 years was 82.5% in the tamoxifen–ovarian suppression group and 78.0% in the tamoxifen group (hazard ratio for recurrence, 0.78; 95% CI, 0.60 to 1.02). At 5 years, the rate of freedom from breast cancer was 85.7% in the exemestane–ovarian suppression group (hazard ratio for recurrence vs. tamoxifen, 0.65; 95% CI, 0.49 to 0.87). Adding ovarian suppression to tamoxifen did not provide a significant benefit in the overall study population. However, for women who were at sufficient risk for recurrence to warrant adjuvant chemotherapy and who remained premenopausal, the addition of ovarian suppression improved disease outcomes. Further improvement was seen with the use of exemestane plus ovarian suppression. (Funded by Pfizer and others; SOFT ClinicalTrials.gov number, NCT00066690.)Keywords
This publication has 17 references indexed in Scilit:
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast CancerNew England Journal of Medicine, 2014
- First international consensus guidelines for breast cancer in young women (BCY1)The Breast, 2014
- Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trialsThe Breast, 2013
- American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast CancerJournal of Clinical Oncology, 2011
- Amenorrhea from Breast Cancer Therapy — Not a Matter of DoseNew England Journal of Medicine, 2010
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast CancerJNCI Journal of the National Cancer Institute, 2009
- Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?Annals Of Oncology, 2008
- Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188)Journal of Clinical Oncology, 2005
- Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?The Lancet, 2000